The Myeloma Beacon » Milatuzumab

Milatuzumab

By: Michelle Spektor; Published: October 4, 2010 @ 10:36 pm | Comments Disabled

Brand Name:
Generic Name:	milatuzumab
Code Name:
Company:	Immunomedics, Inc.
FDA Clinical Phase:	1/2

Description:
Milatuzumab is a humanized monoclonal antibody that targets tumors expressing the CD74 antigen. As the first anti-CD74 antibody studied in human clinical trials, it is currently being investigated as a treatment of multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia.

Clinical Trials:
For a list of clinical trials studying milatuzumab for the treatment of multiple myeloma, see ClinicalTrials.gov ^[1].

Official website for milatuzumab: http://www.immunomedics.com/5clinical/Milatuzumab.html ^[2]

Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/resources/2010/10/04/milatuzumab/

URLs in this post:

[1] ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/results?term=milatuzumab&cond=myeloma

[2] http://www.immunomedics.com/5clinical/Milatuzumab.html: http://www.immunomedics.com/5clinical/Milatuzumab.html

Click here to print.